Replimune Group (NASDAQ:REPL) Stock Price Down 4.3%

Replimune Group, Inc. (NASDAQ:REPL)’s stock price was down 4.3% during trading on Wednesday . The stock traded as low as $10.07 and last traded at $10.12. Approximately 63,890 shares changed hands during trading, a decline of 95% from the average daily volume of 1,180,363 shares. The stock had previously closed at $10.58.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on REPL shares. Barclays boosted their target price on shares of Replimune Group from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Friday, June 7th. JPMorgan Chase & Co. reduced their price objective on shares of Replimune Group from $17.00 to $14.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. HC Wainwright upped their price objective on shares of Replimune Group from $12.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, June 7th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Replimune Group in a research report on Thursday, June 6th.

Replimune Group Stock Down 1.3 %

The stock’s 50-day moving average price is $9.45 and its two-hundred day moving average price is $8.06. The stock has a market capitalization of $692.76 million, a P/E ratio of -3.13 and a beta of 1.25. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. As a group, research analysts expect that Replimune Group, Inc. will post -3.08 earnings per share for the current fiscal year.

Insider Activity at Replimune Group

In related news, CFO Emily Luisa Hill sold 8,938 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $10.18, for a total transaction of $90,988.84. Following the sale, the chief financial officer now directly owns 101,057 shares in the company, valued at approximately $1,028,760.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Konstantinos Xynos sold 15,881 shares of the stock in a transaction on Friday, June 7th. The shares were sold at an average price of $7.50, for a total value of $119,107.50. Following the transaction, the insider now owns 117,131 shares of the company’s stock, valued at approximately $878,482.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the completion of the transaction, the chief financial officer now directly owns 101,057 shares in the company, valued at approximately $1,028,760.26. The disclosure for this sale can be found here. 20.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

A number of institutional investors have recently made changes to their positions in the stock. Algert Global LLC increased its holdings in shares of Replimune Group by 5.4% in the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock worth $756,000 after buying an additional 4,340 shares during the last quarter. Millennium Management LLC grew its holdings in Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after acquiring an additional 2,656,173 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Replimune Group in the 2nd quarter worth $443,000. Cubist Systematic Strategies LLC grew its holdings in Replimune Group by 282.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock worth $650,000 after acquiring an additional 53,313 shares during the last quarter. Finally, Point72 DIFC Ltd bought a new stake in Replimune Group in the 2nd quarter worth $57,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.